These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 1357174)
41. Mechanisms of resistance to 6-aminonicotinamide. Saunders PP; Muhs MA; Arimilli S Anticancer Res; 1996; 16(2):843-8. PubMed ID: 8687139 [TBL] [Abstract][Full Text] [Related]
42. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100 [TBL] [Abstract][Full Text] [Related]
43. Novel nicotinamide adenine dinucleotide analogues as potential anticancer agents: quest for specific inhibition of inosine monophosphate dehydrogenase. Pankiewicz KW Pharmacol Ther; 1997; 76(1-3):89-100. PubMed ID: 9535171 [TBL] [Abstract][Full Text] [Related]
44. Mutation of nicotinamide pocket residues in rat liver 3 alpha-hydroxysteroid dehydrogenase reveals different modes of cofactor binding. Ma H; Ratnam K; Penning TM Biochemistry; 2000 Jan; 39(1):102-9. PubMed ID: 10625484 [TBL] [Abstract][Full Text] [Related]
45. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Jayaram HN; Smith AL; Glazer RI; Johns DG; Cooney DA Biochem Pharmacol; 1982 Dec; 31(23):3839-45. PubMed ID: 6130768 [TBL] [Abstract][Full Text] [Related]
46. Crystallographic investigations of nicotinamide adenine dinucleotide binding to horse liver alcohol dehydrogenase. Eklund H; Samama JP; Jones TA Biochemistry; 1984 Dec; 23(25):5982-96. PubMed ID: 6098306 [TBL] [Abstract][Full Text] [Related]
47. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow. Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199 [TBL] [Abstract][Full Text] [Related]
48. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813 [TBL] [Abstract][Full Text] [Related]
49. Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin. Kusumanchi P; Zhang Y; Jani MB; Jayaram NH; Khan RA; Tang Y; Antony AC; Jayaram HN Cancer Gene Ther; 2013 Jul; 20(7):403-12. PubMed ID: 23764899 [TBL] [Abstract][Full Text] [Related]
50. The conformation of NADH bound to inosine 5'-monophosphate dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy. Schalk-Hihi C; Zhang YZ; Markham GD Biochemistry; 1998 May; 37(20):7608-16. PubMed ID: 9585576 [TBL] [Abstract][Full Text] [Related]
51. Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase. Gebeyehu G; Marquez VE; Van Cott A; Cooney DA; Kelley JA; Jayaram HN; Ahluwalia GS; Dion RL; Wilson YA; Johns DG J Med Chem; 1985 Jan; 28(1):99-105. PubMed ID: 2856943 [TBL] [Abstract][Full Text] [Related]
52. Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy. Berger NA; Berger SJ; Catino DM; Petzold SJ; Robins RK J Clin Invest; 1985 Feb; 75(2):702-9. PubMed ID: 3919063 [TBL] [Abstract][Full Text] [Related]
53. Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides. Reid RC; Yau MK; Singh R; Lim J; Fairlie DP J Am Chem Soc; 2014 Aug; 136(34):11914-7. PubMed ID: 25102224 [TBL] [Abstract][Full Text] [Related]
54. NAD-analogues as potential anticancer agents: conformational restrictions as basis for selectivity. Pankiewicz KW; Zatorski A; Watanabe KA Acta Biochim Pol; 1996; 43(1):183-93. PubMed ID: 8790723 [TBL] [Abstract][Full Text] [Related]
56. Tiazofurin: molecular and clinical action. Weber G; Prajda N; Abonyi M; Look KY; Tricot G Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306 [TBL] [Abstract][Full Text] [Related]
57. The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Cooney DA; Jayaram HN; Gebeyehu G; Betts CR; Kelley JA; Marquez VE; Johns DG Biochem Pharmacol; 1982 Jun; 31(11):2133-6. PubMed ID: 6126195 [No Abstract] [Full Text] [Related]
58. Conserved water-mediated recognition and dynamics of NAD+ (carboxamide group) to hIMPDH enzyme: water mimic approach toward the design of isoform-selective inhibitor. Bairagya HR; Mishra DK; Mukhopadhyay BP; Sekar K J Biomol Struct Dyn; 2014; 32(8):1248-62. PubMed ID: 23829371 [TBL] [Abstract][Full Text] [Related]
59. 1H-, 13C-, 31P-NMR studies and conformational analysis of NADP+, NADPH coenzymes and of dimers from electrochemical reduction of NADP+. Ragg E; Scaglioni L; Mondelli R; Carelli I; Casini A; Tortorella S Biochim Biophys Acta; 1991 Jan; 1076(1):49-60. PubMed ID: 1824754 [TBL] [Abstract][Full Text] [Related]
60. Unusual conformation of nicotinamide adenine dinucleotide (NAD) bound to diphtheria toxin: a comparison with NAD bound to the oxidoreductase enzymes. Bell CE; Yeates TO; Eisenberg D Protein Sci; 1997 Oct; 6(10):2084-96. PubMed ID: 9336832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]